Cern Corporation is featured in Clinical Trial Vanguard, where our Chief Medical Officer, Dr. Melanie Santos, discusses our Cern Device, a new non-drug, light-based therapy designed to address bacterial vaginosis and fungal vaginitis.
This innovative approach combines treatment and diagnostics to support safe, connected care at home, reducing reliance on antibiotics, improving patient experience, and advancing health equity in women’s care.
Thank you to @Moe Alsumidaie and @Clinical Trial Vanguard for highlighting this important conversation and the future of non-drug women’s health therapies.
Read the full interview:
https://www.clinicaltrialvanguard.com/executiveinterviews/shining-light-on-womens-health-a-new-non-drug-vaginal-therapy/
#WomensHealth #ClinicalTrials #Innovation #MedTech #NonDrugTherapy #CernCorporation
